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MODIFIED PAMAM DENDRIMERS IN TUNABLE DRUG-DELIVERY SYSTEMS: A 
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Two specific drug-delivery applications were sought in this work using polyamidoamine 
(PAMAM) dendrimers. One drug-delivery system used a novel dendrimer hydrogel (DH) for 
sustained delivery of anti-glaucoma drugs. In this work, PAMAM G3.0 dendrimers were 
covalently bonded with poly(ethylene glycol) (PEG12000) molecules which were subsequently 
acrylated, resulting in photocurable DH conjugates. For pharmacological studies, DH were 
loaded with a solution of intraocular pressure lowering drugs, brimonidine and timolol maleate, 
 
 
 
 
and were characterized for in vitro release and ex vivo transport and uptake. DH formulations 
were shown to increase the loading of drug molecules, increase transcorneal drug delivery, and 
exhibit sustained-delivery of drug molecules. A second drug-delivery system, utilizing cell-
surface engineering, intended to increase the targeting ability of highly toxic anti-cancer drugs to 
curtail systemic effects. In particular, Qdots and 5-(aminoacetamido) fluorescein-labeled 
polyamidoamine dendrimer G4.5, both of which were coated with amine-derivatized 
polyethylene glycol, were immobilized to the sodium periodate-treated surface of RAW264.7 
macrophages through a transient Schiff base linkage. Further, a reducing agent sodium 
cyanoborohydride was applied to reduce Schiff bases to stable secondary amine linkages. The 
distribution of nanoparticles on the cell surface was observed by fluorescence microscopy and 
was found to be dependent on the stability of the linkages tethering nanoparticles to the cell 
surface. 
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Chapter 1 Introduction 
 
Exciting frontiers in pharmaceutical science research arise from limitations in the innate 
kinetics of drug molecules. Drug molecules have unique profiles in their distribution, uptake, 
absorption, and clearance within the body. These pharmacokinetic properties are typically 
dependent on route of administration(ROA) and formulation. Each ROA has different sets of 
pros and cons depending on the class of drug molecules and the clinical target. The goal in drug 
delivery is to maximize the efficiency of a drug formulation to reach the therapeutic window of 
drug molecules within the body. Drug delivery strategies rely not only on the concentration and 
frequency of dosing, but also on the vehicle of the drug formulation. Traditional clinical 
strategies include, but are not limited to, drugs in solid or liquid form administered 
intravenously, orally, nasally, rectally, topically, or subcutaneously. Therapeutic efficacy is 
based on the innate pharmacokinetics; yet, by using biomaterial research and cellular therapies 
the efficacy of drugs can be enhanced. This project utilizes biomaterial nanoparticle vehicles to 
enhance drug molecules and treatment options. 
Biomaterial research has led to advances in wound healing, tissue engineering, and drug 
delivery. Natural and synthetic classes of biomaterials are used either independently or in 
conjunction with other materials and biologics for desired applications. In this work 
polyamidoamine (PAMAM) dendrimers, a class of synthetic polymeric nanoparticles, are 
explored for their versatile physical and chemical properties. Dendrimers are a highly organized 
polymer branching from an ethylene diamine core structure that are stepwise synthesized to 
create amine terminated (full generation [X.0]) and carboxyl terminated (half generation [X.5]) 
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nanoparticle. The amine and carboxyl functional groups allow for a highly tunable molecule 
using organic chemistry conjugations. This work employs PAMAM dendrimers as a key 
component in biomaterial drug-delivery systems including a topical hydrogel system for 
sustained ocular delivery as well as proof of concept for targeted drug delivery using a cellular 
vehicle hybridized with dendrimers. 
1.1 Anti-glaucoma drug delivery 
Vision, as one of the main sensory inputs, is critical in many aspects of everyday life. 
Visual-impairment can have a huge impact on quality of life, healthcare costs, and 
socioeconomic outcomes. Some of the major causes of visual-field loss are cataracts, age-related 
macular degeneration, diabetic retinopathy, retinal vein-occlusive diseases, and glaucoma. 
Specifically, glaucoma affects 2.7 million people in the United States alone(1). Currently there 
are no cures for glaucoma, but there are effective drug molecules for treating the causes of 
vision-loss in glaucoma patients. The typical treatment for glaucoma are topical eye-drop 
solutions administered multiple times daily; however, this tedious regimen often decreases 
patient compliance which leads to chronic and progressive neurodegeneration of the optic nerve. 
A major goal in anti-glaucoma drug delivery is to decrease the frequency of dosing to increase 
patient compliance and outcomes. This project proposes a topical dendrimer hydrogel co-drug 
formulation as a sustained delivery approach for treatment. 
1.2 Targeted dendrimer delivery with cellular therapy 
Many traditional cancer therapies use highly toxic drugs administered at systemic doses.  
Drug targeting is desired to decrease the harmful effects of chemotherapeutics on healthy cells.  
This project proposes an interdisciplinary approach which utilizes tools from cell biology to 
integrate biomaterial engineering with cancer research. Monocytes have an inherent ability to 
 
 
3 
 
infiltrate tumors based on factors such as hypoxia and chemoattractants.  The overall goal is to 
utilize monocyte-targeting to deliver cancer therapies. This project sought to demonstrate that 
surface modification of monocytes is possible to allow hybridization with a drug-loaded 
biomaterial, specifically half-generation PAMAM dendrimer conjugates (PAMAM G4.5). A 
molecular approach through cell-surface modification of sialic acid residues on monocytes is 
explored. Sodium periodate modifies sialic acid into aldehyde groups which are reactive to the 
amines of G4.5-PEG-NH2 conjugates through transient Schiff linkages. A stabilizing reagent, 
sodium cyanoborohydride, is used to reduce the linkage to a stable amide bond. In review, this 
thesis covers the synthesis and characterization of two drug delivery systems and demonstrates in 
vitro and ex vivo testing to substantiate further work using these novel approaches. 
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Chapter 2 Background and Significance 
 
2.1.1 Glaucoma 
According to a 2014 World Health Organization fact sheet, 285 million people 
worldwide suffer from visual impairment, where up to 80% of incidences are preventable or 
curable. Unoperated-upon cataracts and uncorrected refractive errors account for 76% of all 
cases of visual-impairment, but with treatment visual-field loss is reversible(2). Glaucoma, on 
the other hand, is the number one cause of irreversible blindness in the world(3). With early 
treatment, however, optic nerve damage and visual-impairment can be reduced or prevented. It is 
estimated that currently 60 million people suffer from glaucoma and by 2040 it is projected 112 
million people will have glaucoma(4, 5). There is a clear clinical need to reduce the negative 
effects of the disease which include a lower quality of life and higher economic burden for those 
experiencing vision-loss.  
Glaucoma describes a group of neuropathies which cause a progressive degeneration of 
retinal ganglion cells, cupping of the optic disc, and thinning of retinal nerve fibers(6). The two 
main classifications of glaucoma are open-angle and angle closure. In open-angle glaucoma, 
there is an opening between the iris and cornea, but the aqueous humor outflow is restricted 
through the trabecular meshwork. In angle-closure glaucoma, the drain between iris and cornea 
is closed and outflow through the trabecular meshwork is blocked. Currently there is no 
treatment for reversing nerve damage in glaucoma patients, so treating the main risk factor of 
increased intraocular pressure (IOP) is the primary clinical goal. IOP is a dynamic balance of 
fluid secreted by the ciliary body into the aqueous humor and drainage of aqueous humor. The 
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main treatment options include topical instillation of eye 
drops, which typically target either a decreased production 
of aqueous humor or increased aqueous humor outflow. 
The main clinical IOP-lowering drug classes are described 
below(7). 
 
2.1.2 IOP-lowering therapies 
There are 5 major classes of drugs for lowering IOP in patients; Cholinergic agents, 
prostaglandin receptor analogues, β-blockers, α-adrenergic agonists, and carbonic anhydrase 
inhibitors. Cholinergic agents act on muscarinic receptors on ciliary muscle to increase outflow 
via trabecular meshwork. An example is pilocarpine, which often uses a 4 times daily dosing 
strategy with side effects including myopia, miosis of the pupil, and dimming of vision(7). 
Prostaglandin F receptor(PTGFR) analogues with a once daily dosing increase aqueous humor 
outflow by altering ECM in the ciliary muscle/trabecular meshwork. Side effects of PTGFR 
analogues include lengthening of eyelashes, thickening of eyelashes, and darkening of the iris(7). 
β-adrenergic receptor blockers have an increased tolerability and increased IOP-lowering 
efficacy. β -blocker treatments inhibit β-adrenergic receptors in the ciliary epithelium and help to 
decrease aqueous humor formation. Side effects of timolol maleate at higher dosing frequencies 
include syncope, arrhythmia, and dyspnea. It is thought that decreases in dosing will likely limit 
adverse systemic effects(7). 
Figure 2.1 Depiction of aqueous humor outflow 
adapted from https://www.aao.org/eye-
health/diseases/glaucoma-causes 
 
 
6 
 
α-adrenergic agonists, such as brimonidine, lower IOP through stimulation of α2-
adrenergic receptors which decreases aqueous humor in flow and increases uveoscleral outflow. 
Similar to β -blockers, α-adrenergic agonists only lower IOP during the day(7). 
Carbonic anhydrase inhibitors are another IOP-lowering class and they decrease aqueous 
humor formation by inhibiting carbonic anhydrase II in the ciliary epithelium. Carbonic 
anhydrase inhibitors are typically second line agents and are effective day or night(7). 
There are also FDA approved drug combination therapies that aim to simultaneously 
decrease aqueous humor inflow and increase outflow. These multi-drug formulations have 
multiple mechanisms of action and are more effective than single drugs at lowering IOP. The 
main issue of IOP lowering drugs is not necessarily the efficacy of action, but the efficiency of 
delivery and dosing regimen required to maintain therapeutic drug levels in patients. 
2.1.3 Ocular drug delivery 
Treatment of ocular diseases involves optimizing drug bioavailability in ocular tissues for 
a therapeutic response, where transcorneal permeation is the primary route of drug transport into 
the aqueous humor and conjunctival absorption is considered an alternative route of transport. 
Systemic drug delivery is typically not feasible for ocular drugs due to the blood-retinal and 
blood-aqueous barriers. The main barriers in topical ophthalmic drug delivery include corneal 
epithelial tight junctions, lacrimal clearance, conjunctival absorption, metabolism, and 
inadvertent protein binding(8). The shortfalls of eye drop formulations include quick precorneal 
clearance and low bioavailability of drug leading to a higher dosing frequency for patients. A 
high dosing frequency often leads to lower patient compliance and increased side effects. One 
solution to increase drug absorption into ocular tissues is to increase corneal residence time via 
electrostatic interactions with negatively charged cell membranes as well as binding with native 
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proteins such as mucin. Creating a more bioadhesive formulation would help alleviate some of 
the drug loss due to tearing. The main attachment targets for bioadhesion on the ocular surface 
are the mucous coat on the surface tissue and epithelial tissues(9). 
Some ocular drug delivery formulations have used water soluble polymers, nanoparticles, 
liposomes, cellulose derivatives, mucus glycoproteins, and hyaluronate to increase corneal 
residence time through increased viscosity and bioadhesion. Likewise, in situ forming gels 
activated by pH or temperature have also been used to enhance transcorneal delivery. 
Dendrimers have been tested as ophthalmic vehicles for pilocarpine nitrate; in this work they 
were proposed to exhibit bioadhesiveness and increased corneal residence times. Other solutions 
aim to transiently increase transcorneal delivery through use of absorption promoters or 
penetration enhancers.  Examples of penetration enhancers include calcium chelators (such as 
EDTA), surfactants, and micelles which disrupt epithelial tight junctions to allow increased 
paracellular permeation(9, 10). An ideal ocular formulation will likely combine characteristics 
including increased viscosity, increased precorneal residence, increased transcorneal transport, 
sustained delivery, and concomitant drugs. 
2.1.4 Hydrogels 
Physical and chemical hydrogels 
Hydrogels are networks of polymers and colloids with either physical or chemical 
crosslinking that retain aqueous solutions. Physical hydrogels are networks held together by 
polymer entanglements, ionic interactions, or hydrogen bonding. Physical hydrogels can include 
anionic and cationic polymer combinations such as alginate and chitosan that self-entangle into 
gels. Polymers such as PEG-PLA, agarose, and gelatin can dissolve in water as random 
structures and can organize into helices upon heating or cooling processes to form rigid and 
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reversible sol-gels(11, 12). Chemical hydrogels have networks linked with covalent bonds and 
are the most frequently explored class in hydrogel research. Chemical hydrogels involve 
covalently crosslinking functional side chains or end groups of polymers with monomers or 
chemical treatments. UV and ionizing radiation are also used as crosslinking methods through 
free radical polymerization. Typically, physical hydrogels are weaker, more transient, and less 
customizable than chemical hydrogels(13).  
Natural and synthetic hydrogels 
Other than physical or chemical crosslinking, hydrogels can also be characterized as 
either having synthesized or naturally occurring components. Natural hydrogels are formed from 
proteins and polysaccharides including extracellular matrix proteins such as collagen and gelatin 
or polysaccharides such as agarose or alginate. Natural hydrogels typically exhibit better 
qualities of biocompatibility and biodegradation, but they are often less-customizable. Synthetic 
hydrogels include artificial polymers that are synthesized in labs. Artificial hydrogels are highly 
tunable and easily tailored to specific applications in the synthesis process. Water content, 
mechanical properties, chemical properties, mesh size, and polymer length can all be customized 
in synthetic hydrogels for specific biomedical functions(13). 
Hydrogels in biomedical applications 
Hydrogels show promising characteristics for controlled release of bioactive molecules 
and as scaffolds for cell growth. Design considerations for hydrogels include gelation conditions, 
biodegradation, biocompatibility, and synthesis. Hydrogels can also respond to biological 
conditions such as changes in temperature, pH, and ionic conditions to swell or contract; such 
responses by hydrogels allow exploitation of local conditions in delivery systems. Examples of 
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commercially available hydrogels include wound dressings, drug delivery vehicles, tissue 
scaffolds, contact lenses, diapers, and biosensors(13). 
Dendrimer hydrogels 
Dendrimer nanoparticles, with their highly branched architecture, are ideal molecules for 
crosslinking into hydrogel networks due to their surface functionality. Previous work with 
PAMAM dendrimers tested the effects of PEG length and degree of PEGylation, PEG molecules 
per dendrimer, in formation of photocurable hydrogels. It was demonstrated that PEG12,000 
created effective solid hydrogels after coupling with acrylate groups. Demonstrating synthesis of 
dendrimer hydrogels (DH) shows promise in drug delivery and tissue engineering applications. 
The hydrogel network is potentially a scaffold for cell growth or as a substrate for loading both 
hydrophobic and hydrophilic drug molecules. Recent research demonstrates PEGs with 
predetermined breaking points could add further control to PEGylated DHs and lead to new 
routes of biodegradation and sustained delivery(14, 15). 
2.2 Dendrimers 
Dendrimers are a class of nanoparticles with a highly organized structure resembling the 
branches or roots of trees. Expanding from a central core molecule, each stepwise monomer 
addition branches at a covalent bond to double the existing number of terminal groups. As the 
dendrimer expands, there is an incremental increase in molecular weight, diameter, and surface 
groups.  
Dendrimers are favorable vehicles for drug delivery due to their surface group 
functionality, low polydispersity, hydrophobic cores, and globular structure. Full-generation 
(polycationic) and half-generation (polyanionic) dendrimers, with their amine and carboxyl 
terminal groups, allow for an array of organic chemistry coupling techniques. Polycationic 
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dendrimers have a shorter blood circulation time as electrostatic interactions with negatively 
charged cell walls lead to a rapid clearance whereas polyanionic dendrimers can have lower 
cytotoxicity and longer circulation time in the body as they are repelled by the negative surface 
potentials of cell walls. Individual dendrimers can be engineered for biocompatibility, drug 
loading, and targeting to satisfy a variety of biomedical applications. Specifically, PAMAM 
dendrimers tethered with poly(ethylene glycol) (PEG) chains have stealth properties, solubility in 
a range of solvents, and high biocompatibility as they are not readily recognized by the 
reticuloendothelial system. The propensity of dendrimers for drug-loading is an advantage over 
other systems as multiple drug molecules can be covalently bonded to surface functional groups 
of a single dendrimer for concentrated delivery. In addition to covalent drug loading, the 
hydrophobic backbone core of dendrimers can encapsulate hydrophobic drugs into the network 
with or without surface group loading. These unique properties allow dendrimer systems to have 
dual drug-loading to optimize therapeutic responses. Hybridized dendrimers have been used in 
polymeric micelles, hydrogels, and targeted drug-delivery with a wide range of functions. The 
biological properties and high modification potential of dendrimers makes them ideal building 
blocks for many biomedical applications. PEGylated dendrimers show low toxicity, low 
immunogenicity, and increased circulation time in the body and are ideal for targeted drug 
delivery(16-20).  
2.3 Cellular Delivery of Anticancer Drugs 
2.3.1 Tumor vasculature 
Angiogenesis and irregular vasculature are attributes of solid tumors.  Solid tumors are 
also associated with vascular permeability factors and poor lymphatic drainage.  The irregular 
vasculature and permeability factors result in a leaky vasculature which allows nutrients and 
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oxygen to reach rapidly growing tumors; however, this leaky vasculature also facilitates an 
enhanced permeability of macromolecules and lipid particles into interstitial space.  Once in the 
interstitial space, macromolecules accumulate due to the poor lymphatic drainage.  These traits 
are known as enhanced permeability and retention (EPR).  EPR can be a useful tool in treating 
tumors using nanoparticle and polymer conjugated chemotherapeutics(21-23).  A limiting factor 
in using macromolecules or nanoparticles for drug delivery is the mononuclear phagocyte 
system(MPS). In the MPS, mononuclear cells are responsible for phagocytosing foreign particles 
to remove them from circulation.  The addition of polyethylene glycol (PEG) to drug carriers 
creates stealth particles which can evade the MPS. PEGylation is a strategy which helps 
nanoparticle carriers to avoid phagocytosis and allows particles to accumulate in tumor tissues 
due to the EPR effect(23, 24). 
Even if drug molecules accumulate in the extratumoral region due to EPR, there may not 
be sufficient distribution within tumors as many solid tumors have densely packed cells with 
necrotic centers.  Nutrient-poor regions within tumor cores results in the formation of areas of 
hypoxia, establishment of chemotactic gradients, and heterogeneous microenvironments. 
Chemotherapeutic drugs struggle to diffuse passively into tumor cores, limiting the therapeutic 
response which potentially leads to drug resistances(25). Additionally, inefficient delivery 
necessitates the use of considerably higher drug concentrations, with resultant increased toxicity 
to normal cells, a major limiting factor when determining drug dosage. Thus, it is essential to 
develop methodology to deliver targeted-drug payloads into tumors to increase the efficacy and 
safety of chemotherapies.  In this regard, a cellular-based delivery approach promises 
considerable advantages over standard drug formulations for treatment. 
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2.3.2 Monocyte migration 
Blood monocytes play important repair roles in immune responses and are recruited into 
damaged or pathologic tissues in response to hypoxic or chemoattractant gradients(26). It has 
been demonstrated that monocytes have an innate ability to migrate to hypoxic areas, 
specifically, inside tumor spheroids(27). Once they are distributed into tissues, monocytes 
differentiate into macrophages. Basic monocyte and macrophage functions include phagocytosis 
of foreign particles, cytokine production, and antigen presentation. Monocytes and macrophages 
mediate immune and inflammatory responses and are important for recruitment of more immune 
cells into tissues(28). The migratory abilities of monocytes are well-documented and, when 
activated in response to gradients as mentioned above, could potentially act as suitable delivery 
vehicles for targeted therapeutics(29). Monocyte chemoattractant protein-1 (MCP-1) expression 
in tumors is shown to recruit monocyte-derived macrophages; studies demonstrate that an 
increase in MCP-1 lead to an increase in intratumoral macrophage invasion(30, 31).   
2.3.4 Cellular therapies and metabolic engineering 
Some chemotherapeutics, such as doxorubicin (DX), have a short plasma half-life.  DX 
also has a wide biodistribution leading to cardiotoxicity at higher dosages(32, 33). To minimize 
negative effects on healthy tissues in vivo, drugs and nanoparticles have been conjugated with 
PEG  to improve biocompatibity; PEGylating nanoparticles can increase plasma half-life and 
affect biodistribution of drugs(24). Additionally, DX has been shown to distribute poorly in 
hypoxic, acidic regions of tumors(34). 
The proposed research aims to develop a hybrid vehicle consisting of 
monocytes/macrophages to which doxorubicin has been conjugated on the cell surface via 
polyamidoamine (PAMAM) dendrimer nanoparticles, to test functionality of both monocytes 
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and drug, and to investigate migration into and delivery of drug payload to tumor spheroids in 
vitro.   
Pathways in metabolic engineering can be used to facilitate chemical modification of 
cells, in order to endow them with specific new or enhanced properties. Sialic acid residues are 
present on mammalian cell lines and can be modified by sodium periodate (NaIO4) into amine-
reactive aldehyde groups. The NaIO4 modification allows aldehydes to couple with amines to 
form a transient Schiff-based linkage(35, 36). When the bond is exposed to another species, 
sodium cyanoborohydride (Na CBH3), the linkage is reduced to a stabilized secondary amine 
bond(37). These surface techniques allow for conjugation of amine terminated and drug-loaded 
biomaterials on a cell exterior. The external attachment of drug molecules is helpful to protect 
the host cell. The use of tumor-targeting monocytes as delivery vehicles is a promising lead in 
drug therapy. 
In this study, half generation PAMAM dendrimers with 128 carboxyl surface groups 
(G4.5) are used. When combined with another polymer, polyethylene glycol (PEG), these 
nanoparticles exhibit increased water solubility and biocompatibility(38). Administering N-
hydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) 
hydrochloride allowed COOH surface conjugation to NH2 groups. PEG diamine are conjugated 
to activated PAMAM nanoparticles and leave an active NH2 to bind to cell-surface 
aldehydes(39). When the degree of PEG loading is high, hydrophobic drugs can be encased at 
the dendrimer core(20). The avenue for immobilizing drug-loaded nanoparticles on modified cell 
surfaces is evident and has direct advantage over unbound drug formulations. 
The overall hypothesis is that targeted delivery of chemotherapeutic drugs will enhance 
therapeutic response and enable the use of lower drug concentrations when applied to patients in 
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the future. Thus, the goal of the proposed research is to apply what is current knowledge of 
cancer biology, immune function, surface science, and biomaterials to create a novel, cutting 
edge drug delivery vehicle for cancer chemotherapeutics.  This second project proposes to 
immobilize drug-loaded nanoparticles on the surface of monocytes for targeted tumor therapy. 
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Chapter 3 Polyamidoamine Dendrimer Hydrogel for Enhanced Delivery of 
Anti-glaucoma Drugs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following chapter is adapted from a manuscript accepted in Nanomedicine: Nanotechnology, 
Biology and Medicine, July 2012, Volume 8(5), pages 776-783, DOI: 
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3.1. Abstract 
Dendrimer hydrogel (DH), made from UV-cured poly(amidoamine) PAMAM dendrimer 
G3.0 tethered with three polyethylene glycol (PEG, 12000 Da)-acrylate chains (8.1% w/v) in 
pH7.4 phosphate buffered saline (PBS), was studied for delivery of anti-glaucoma drugs— 
brimonidine (0.1 % w/v) and timolol maleate (0.5% w/v). DH was found to be mucoadhesive 
and cytocompatible with human corneal epithelial cells (HCETs). The solubility of brimonidine 
in DH was 77.6% higher than that in plain PBS. Both drugs were slowly released over 56-72 
hours by DH in vitro. As compared to eye drop formulations (PBS drug solutions), DH resulted 
in substantially higher degrees of intracellular drug uptake by HCETs and cumulative transport 
across bovine cornea for both drugs as well as significantly higher adsorption of timolol maleate 
in corneal epithelium, stroma, and endothelium. This work demonstrated that DHs can enhance 
delivery of anti-glaucoma drugs in multiple aspects and represent a novel platform for ocular 
drug delivery. 
3.2 Background 
There is a high clinical demand for treating ocular diseases and priority is in increasing 
the delivery efficiency of therapeutic drugs to the eye. To date, safe and effective treatments of 
most ocular diseases rely heavily on topical applications due to ease of use and low-cost 
manufacturing. Conventional dosage forms including aqueous solutions, suspensions, and 
ointments that are administered topically and dominate the global market of ocular drug delivery, 
accounting for nearly 90% of marketed formulations.  
To treat chronic eye diseases such as glaucoma, considerable efforts have been placed on 
exploring new topical drug carriers and formulations to increase ocular residence time of drugs 
and increase drug adsorption. Consequently, enhanced drug delivery helps extend the duration of 
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drug activity and reduce dosing frequency for patient compliance improvement. Non-
conventional delivery systems and formulations for topical application of anti-glaucoma drugs 
are under rapid development. Mucoadhesive polymers such as hyaluronic acid and chitosan are 
able to enhance retention time and drug penetration through the corneal barriers due to their 
bioadhesiveness(9, 40, 41). In situ-forming hydrogels are liquid upon instillation and form 
viscoelastic gels in response to environmental changes such as pH or temperature(42-46). The 
application of in situ-forming hydrogel results in prolonged precorneal residence time and 
increased ocular bioavailability. In addition, since cationic liposomes can be preferentially 
captured at the negatively charged corneal surface, they have been investigated as carriers for 
delivery of ocular therapeutics(47). Nanoparticles such as PAMAM dendrimers, 
polyguanidilyated dendrimers, and poly(butylcyanoacrylate) nanoparticles have also been shown 
to improve ocular drug delivery efficiency(10, 19, 48-51). 
Recently, we have developed a polyamidoamine (PAMAM) dendrimer hydrogel (DH) 
platform, which is made from UV-cured PAMAM dendrimer tethered with polyethylene glycol 
(PEG)-acrylate chains(15). By tuning concentration and its structural parameters such as the 
degree of PEGylation, PEG length, and acrylate density on the dendrimer, photoreactive 
dendrimer PEG acrylate in aqueous solutions can be partially crosslinked to form viscous 
solutions or completely crosslinked to form “no-flow” gel in situ upon exposure to UV light in 
the presence of an eosin Y-based photoinitiator(15). PAMAM dendrimers are highly branched 
nanoparticles with numerous surface groups and charges(52). Different from gels made from 
aliphatic polyester-ether hybrid dendritic-linear polymers reported for corneal laceration 
repair(53-55), the DH network allows for simultaneous delivery of both hydrophobic and 
hydrophilic drugs as needed. The interior hydrophobic core of the dendrimer can encapsulate 
 
 
18 
 
hydrophobic compounds and increase their water solubility and loading amounts(17, 56). When 
crosslinked, the PEG network can accommodate hydrophilic drugs. DH is likely to have 
excellent cytocompatibility owing to the PEG component. Furthermore, the cationic charges 
conferred by the DH possess unique structural characteristics and desirable properties for drug 
delivery. Figure 3.1 shows a representation of a drug-loaded dendrimer hydrogel. 
 
Figure 3.1 Representation of drug-loaded dendrimer hydrogel 
 
For ocular drug delivery, the DH promises to have properties superior to dendrimer or 
PEG gel alone, each of which have been separately shown to be efficient as ophthalmic vehicles. 
Therefore, the objective of this work is to demonstrate the feasibility of utilizing DH as a topical 
formulation for ocular drug delivery. The anti-glaucoma drugs brimonidine and timolol maleate 
were used as model drugs. Mucoadhesiveness of the DH was characterized in terms of its 
interaction between mucin particles. Cytotoxicity of DH formulations and their ability to 
enhance water solubility of hydrophobic brimonidine were studied. Further, in vitro drug release, 
cellular uptake, ex vivo transcorneal transport, and ex vivo eye tissue uptake of the two drugs 
mediated with DH formulations were examined.  
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3.3 Methods and Materials 
3.3.1 Synthesis of photoreactive PAMAM G3.0-PEG-acrylate conjugates 
Photoreactive PAMAM G3.0-PEG-acrylate conjugates were synthesized at room 
temperature following our previously reported procedure with modification(15). According to 
Scheme 1, PEG diol (12000 g·mol-1) (1 eq.) dissolved in tetrahydrofuran (THF) was reacted with 
acryloyl chloride (1 eq.) first in the presence of triethylamine (TEA) (1 eq.). After overnight 
reaction while stirring, the salt was removed by centrifugation. The resultant OH-PEG-acrylate 
in the supernatant was further reacted with 4-nitrophenyl chloroformate (NPC) (1 eq.) and TEA 
(1 eq.). The reaction proceeded overnight while stirring. Upon the centrifugal removal of the salt, 
the resultant NPC-PEG-acrylate was dried through rotary evaporation. NPC-PEG-acrylate was 
then coupled to PAMAM dendrimer G3.0 in dimethylformamide. After 24 h reaction, G3.0-
PEG-acrylate conjugates were precipitated in cold ether, dialyzed against deionized water, and 
freeze-dried. The conjugates were characterized with 1H-NMR spectroscopy(15, 38, 56). G3.0 
coupled with an average of 3 PEG acrylate chains (MW=~43,000 g mol-1) was obtained and used 
to prepare anti-glaucoma drug formulations. FI-IR spectra were obtained from solution cast films 
on KBr discs using a Nicolet Magna IR 760 spectrometer.  
 
3.3.2 Preparation of anti-glaucoma drug formulations 
To prepare combination drug formulations based on DH, 40.5 mg of G3.0-PEG-acrylate 
was first dissolved in 500 µL of pH 7.4 phosphate buffered saline (PBS) to have a final 
concentration of 8.1% (w/v) in PBS. Afterwards, 0.5 mg of brimonidine and 2.5 mg of timolol 
maleate were added to the G3.0-PEG-acrylate PBS solution and then the solution was vortexed. 
Following addition of 25 µL of eosin Y photoinitiator solution (0.1% w/w eosin Y, 40% w/w 
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triethanolamine, and 4% w/w 1-vinyl-2 pyrrolidinone), the solution was exposed to long-
wavelength (365 nm) UV light for 30 min and kept overnight under ambient light prior to use. 
No further treatment was conducted. The prepared combination drug formulations 
(brimonidine/timolol/DH) contained 0.1% (w/v) brimonidine and 0.5% (w/v) timolol maleate on 
the basis of initial loading quantities. Single drug DH formulations (i.e., brimonidine/DH and 
timolol/DH) were prepared by adding 0.5 mg of brimonidine or 2.5 mg of timolol maleate to 500 
µL of 8.1% w/v G3.0-PEG-acrylate PBS solution, mixing the solution with 25 µL of eosin Y 
photoinitiator solution, and exposing the solution to UV light for 30 min. PBS control 
formulations (i.e., brimonidine/PBS, timolol/PBS, and brimonidine/timolol/PBS) were prepared 
by dispersing 0.5 mg of brimonidine and 2.5 mg of timolol maleate individually or in 
combination in 500 µL of PBS.  
 
3.3.3 Mucoadhesion tests 
To assess mucoadhesive properties of DH formulations, zeta potential was measured for 
quantitative analysis of interaction between mucin particles and DH. To prepare mucin particles, 
an appropriate amount of gastric porcine mucin was suspended in pH 7.4 PBS and agitated 
overnight to generate a 1% (w/v) mucin solution. The solution was then subjected to microprobe 
sonication two times at full power using a Branson Sonifier 450 20kHz model sonication 
unit(57). 700 µL of mucin particle solution was added to 100 µL of 8.1% (w/v) DH solution. 
Zeta potential of mucin particles before and after mixing with DH solution was determined using 
a Malvern ZetaSizer Nano ZS90 (Malvern Instruments Inc, Westborough, MA). 
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3.3.4 Cytotoxicity assays 
To test cytotoxicity of DH formulations, human corneal epithelial cells (HCET, passage # 
40) were plated in a 96-well plate at a seeding density of 5000 cells per well and allowed to grow 
for 24 hours in serum-containing medium. The medium was removed and the cells were 
incubated in serum free medium (200µL); the DH formulations (30µL each, n=3) were added to 
the cells or the cells remained untreated (control) for 24 hours. At the end of 24 hours, the media 
containing the DH formulations was removed and 200 μL of fresh serum free medium was added 
to each well. 20 μL of 5 mg/ml MTT reagent, dissolved in PBS (pH 7.4), was added to each well 
and incubated at 37 °C for 4 hours. The medium was aspirated and the resultant formazan 
crystals were dissolved in 200 μL of dimethyl sulfoxide. The absorbance of the developed color 
was measured at 540 nm using a microplate reader. An identical set of cells were used for a 
protein content assay. Protein content was quantified using the Micro BCA Protein Assay Kit 
(Pierce Biotechnology, Rockford, IL), where bovine serum albumin was used as a standard.  
 
3.3.5 Brimonidine solubility studies 
To estimate the degree of solubilization of hydrophobic brimonidine (Sigma-Aldrich, St. 
Louis, MO) in the DH formulation, an excess amount of brimonidine was added to G3.0-PEG-
acrylate PBS solution (8.1% w/v) and vortexed. G3.0-PEG-acrylate was the precursor of the DH 
and was not treated with UV light to avoid the interfering absorption after formation of a turbid 
gel. Following overnight equilibration at room temperature, the solution saturated with 
brimonidine was vortexed again and then centrifuged to remove solid drug residue(56). The 
supernatant was collected and diluted by a factor of 100 in PBS. Its absorbance value (Y) at 248 
nm was recorded on a GENESYS™ 6 UV-Visual spectrophotometer. Thus, drug concentration 
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[C] (μg/mL) was determined using the following regression equation: [C]=(Y-0.005)/0.063 (58). 
Following the same procedure, the solubility of brimonidine in plain PBS at room temperature 
was determined for comparison. Measurements were done in duplicate.  
 
3.3.6 In vitro drug release studies 
Drug release studies were performed based on a brimonidine/timolol maleate codrug DH 
formulation. Briefly, 100 μL of drug-loaded gel solution or eye drop solution was transferred to 
Spectra/Por® 7 (MWCO 2000) dialysis tubing (Spectrum Laboratories, Inc., CA) and suspended 
in 1.5 mL of PBS (pH=7.4) containing 0.05% sodium azide in 2 mL microcentrifuge tubes. The 
tubes were maintained at 37 ± 2 °C and constantly shaken in a shaker incubator. At pre-
determined time intervals up to 72 hours, the medium outside the dialysis tube was replaced with 
1.5 mL of fresh PBS, which was pre-equilibrated to 37 ± 2°C. The amount of drug released into 
the dissolution medium was analyzed with LC-MS/MS.  
 
3.3.7 In vitro drug uptake studies  
Human corneal epithelial (HCET) cells (passage#40) were seeded in a 48 well-plate at a 
seeding density of 5000 cells per well and allowed to grow for 24 hours in serum-containing 
medium. The next day, the cell culture medium was removed and the cells were incubated in 
serum-free medium (1mL) and the cells were exposed to 150 µL of brimonidine or timolol 
maleate gel formulation (n=4), whereas the cells exposed to brimonidine and timolol maleate eye 
drop solutions were used as control. After 1 hour exposure at 37 ºC, the cells were washed twice 
with 200 µL of cold neutral pH 7.4 PBS and twice with 200 µL of cold acidic pH 5.0 PBS. Cells 
were lysed by adding 200 µL of 1% (w/v) Triton X-100 solution to each well and allowed to 
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stand for 30 minutes. The cell lysate was scraped from the plate and a suspension was prepared. 
To analyze drug concentration, 100 µL of the cell lysate was diluted to 500 µL using acetonitrile, 
vortexed for 10 minutes, and centrifuged to collect supernatants and cell lysates. The contents of 
brimonidine and timolol maleate in cell washes, supernatants, and cell lysates were analyzed 
with LC-MS/MS. 
 
3.3.8 Ex vivo transcorneal transport studies 
Corneas were isolated from freshly excised bovine eyes obtained from a local slaughter 
house, and mounted in Ussing chambers. 50 μL of DH formulation/eye drop formulation (n=5) 
containing 0.1 % brimonidine (50 μg) and 0.5 % timolol (250 μg) was diluted with assay buffer 
(pH 7.4) to 1.5 mL and added to the donor side. The following compounds were used for the 
preparation of assay buffer: NaCl (122 mM), NaHCO3 (25mM), MgSO4 (1.2 mM), K2HPO4 (0.4 
mM), CaCl2 (1.4 mM), HEPES (10 mM), and glucose (10 mM). At 1, 2, 3, 4, and 6 h, 200 μL of 
sample solution was collected on the receiver side and then immediately replaced with 200 μL of 
fresh assay buffer. At 6 hours, sample solutions on both sides were collected, and the tissues 
were removed from the chambers. Drug contents in the sample solutions were analyzed with LC-
MS/MS.  
 
3.3.9 Ex vivo drug uptake studies 
Freshly excised bovine eyes were rinsed with PBS and incubated in a muffin pan partially 
filled with PBS, as per a previously reported method(59). A solution of gel formulation or eye 
drop formulation (50 μL) (n=4) was administered to the corneal surface and allowed to drain. 
Every 15 minutes, 50 μL of fresh PBS was instilled as an eye drop to simulate tear exposure and 
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to maintain corneal moisture. At 1 hour, the bovine eyes were dissected to collect aqueous humor 
and corneal tissues including epithelium, stroma, and endothelium. Drug contents in the excised 
eye tissues were quantified using LC-MS/MS.  
 
3.3.10 Drug extraction and recovery 
A liquid-liquid method for extraction of brimonidine and timolol from bovine ocular 
tissues was first validated to determine the percentage extraction recovery of brimonidine and 
timolol (Table 3.1). An extraction recovery study was performed at 500 ng/mL of analytes for all 
the corneal layers isolated in this study. Briefly, 20 mg of each tissue (epithelium, stroma, 
endothelium; n = 5) was weighed in a glass tube. 20 μL of standard analyte solution containing 
25 μg/mL of timolol and brimonidine, 10 μL of dorzolamide solution (25 μg/mL) as internal 
standard (IS) and 470 μL of 2 % NaOH solution (pH 12.8) was added to the above tube. Since 
both analytes as well as IS are highly basic molecules, 2 % NaOH solution was used to keep 
them under unionized state. Tissues were homogenized using a hand homogenizer on an ice bath 
followed by sonication for 10 minutes. To the tissue homogenates 4 ml of ethyl 
acetate/dichloromethane mixture (1:1 v/v) was added. The mixture was vortexed for 15 minutes 
and then subjected to centrifugation for 10 minutes to collect the organic layer. The organic layer 
was blow-dried with nitrogen at 40 ºC. The residue, after evaporation, was reconstituted with 1 
mL of acetonitrile-water (75:25 v/v) and subjected to LC-MS/MS analysis. The percentage 
extraction recovery was calculated using the following formula:(analyte concentration detected 
in the tissue ×100)/(initial concentration of the analyte used). 
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Table 3.1 The percent extraction recovery (%) of brimonidine and timolol maleate at 500 ng/mL from bovine corneal epithelium, 
stroma, and endothelium (n=5) 
 
Tissue Brimonidine Timolol maleate 
Corneal epithelium 123.0 ± 21.7 103.0 ± 17.6 
Corneal stroma 118.0 ± 41.2 120.0 ± 10.1 
Corneal endothelium 112.0 ± 17.7 114.0 ± 26.0 
 
 
3.3.11 Drug quantification in ex vivo uptake studies 
After validating the percentage extraction recovery of the liquid-liquid extraction method, 
drug content in the tissue samples from ex vivo uptake study was estimated. Ocular tissues were 
weighed and mixed with 490 µL of 2 % NaOH and 10 µL of 25 μg/mL dorzolamide (internal 
standard) in 10 mL glass tubes, followed by the same procedure as mentioned in the extraction 
and recovery section. To analyze drug levels in the aqueous humor, 50 μL of aqueous humor (~ 
48 mg) was diluted 5 times with acetonitrile-water mixture (75:25 v/v) containing dorzolamide 
as an internal standard and subjected to LC-MS/MS analysis. A final concentration of the 
internal standard was maintained at 250 ng/mL for all processed samples as well as standard 
samples used for preparing the calibration curve. 
 
3.3.12 LC-MS/MS analysis  
LC-MS/MS was applied to determine the concentrations of brimonidine and timolol 
maleate. An API-3000 triple quadrupole mass spectrometry (Applied Biosystems, Foster City, 
CA, USA) coupled with a PerkinElmer series-200 liquid chromatography (Perkin Elmer, 
Walthm, Massachusetts, USA) system was used. Analytes were separated on Zorbax extended 
C18 column ( 2.1 x 50 mm, 5 µm) using 5 mM ammonium formate in water (A) and  acetonitrile 
(B) as mobile phase. The linear gradient elution at a flow rate of 0.3 ml/min with total run time 
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of 6 min was as follows: 60% A (0–1.0min), 10% A (2.0– 4.0 min), and 60% A (4.5-6.0 min). 
Brimonidine, timolol and dorzolamide (internal standard) were analyzed in positive ionization 
mode with the following multiple-reaction monitoring (MRM) transitions:  292 → 212 
(brimonidine); 317 → 261 (timolol); and 325 → 199 (dorzolamide).  
 
3.3.13 Statistical analysis 
Data were analyzed with analysis of variance (ANOVA) followed by t-test for pairwise 
comparison of subgroups using SigmaPlot 11.0 (Systat Software Inc., San Jose, CA). P values 
<0.05 were considered statistically significant. 
 
3.4 Results 
3.4.1 Characterization of dendrimer hydrogel (DH) formulations 
Intermediate OH-PEG-acrylate and final product G3.0-PEG-acrylate (Scheme 1) were 
characterized with FT-IR. As shown in Figure 1, a broad absorption band at 3199-3678 cm-1 was 
attributed to O-H stretching of the hydroxyl end group of PEG. A strong absorption band at 2889 
cm-1 was attributed to C-H stretching of PEG. The presence of acrylate group of PEG was 
confirmed by an absorption band at 1728 cm-1 corresponding to C=C stretching and a band at 
1650 cm-1 corresponding to C=O stretching. Because of the remaining primary amine groups on 
the dendrimer surface, a broad absorption band at 3125-3166 cm-1 indicates N-H stretching. PEG 
was coupled to PAMAM dendrimer via an amide linkage. The C=O stretching band at 1650 cm-1 
became stronger due to the formation of amide linkages and indicates the success of the coupling 
reaction.  
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As a viscous gel solution is preferred to solid gel in ocular drug delivery due to its ease of 
handling and application, PAMAM dendrimer G3.0 coupled with an average of 3 PEG-acrylate 
chains was used to make viscous gel solutions for preparation of anti-glaucoma drug 
formulations. Mucoadhesiveness of DH formulation was demonstrated by zeta potential 
measurements. The zeta potential of 1% w/v mucin particles in PBS was -7.13±0.77 mv. The 
zeta potential changed to -3.6±1.50mv after mixing with DH solution. This shift towards zero 
 
A 
B 
Figure 3.2 Synthesis route (A) and FT-IR spectrum (B) of G3.0-PEG acrylate conjugates. 
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was attributed to the aggregation of mucin particles as a result of adsorption of DH on the mucin 
particles(57).  
The effect of plain DH formulations on cellular response was assessed. According to the 
MTT assay (Figure 3.3), the DH formulation including photoinitiator neither caused toxicity to 
HCET cells nor induced cell proliferation rate. The protein content in the cells was quantified by 
using the Micro BCA protein assay kit. It was shown that the protein content in the cells treated 
with the DH formulation was just 9.3% less than in the control. 
 
Figure 3.3 Effects of DH gel formulation on HCET cellular activity in comparison with the control. MTT assay and BCA Protein 
Assay Kit(Pierce) 
 
3.4.2 Drug water solubility enhancement  
It has been documented that PAMAM dendrimers are able to increase the water solubility 
of hydrophobic compounds by encapsulating them inside the hydrophobic core(20). PEGylation 
can augment the water solubility enhancement properties of dendrimers presumably due to 
stabilizing and shielding effects of the PEG layer(17, 56). As dendrimers have been integrated 
into a hydrogel network, one envisioned property of a dendrimer hydrogel is its ability to 
encapsulate hydrophobic drug molecules inside the dendritic cores, while simultaneously 
allowing the loading of hydrophilic drugs in the PEG network. To test the ability of the 
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dendrimer hydrogel to enhance water solubility of hydrophobic drugs, brimonidine was used in 
this work. Unlike the commonly used water-soluble brimonidine tartrate in ophthalmic solutions, 
brimonidine has a limited solubility in aqueous solutions. Our studies revealed that the solubility 
of brimonidine was 392 μg/mL in plain PBS. In sharp contrast, the solubility of brimonidine 
dramatically increased to 696 μg/mL in DH formulation, representing a 77.6% increase. 
 
3.4.3 In vitro drug release studies 
DH formulation resulted in extended in vitro release of brimonidine and timolol maleate. 
It was observed that drug release was sustained 
for nearly 72 hours for brimonidine (Figure 3.4-
A) and nearly 56 hours for timolol maleate 
(Figure 3.4-B). Contrastingly, drug in eye drop 
formulations was released quickly. Both 
brimonidine and timolol maleate were released 
completely from eye drop formulations within 
90 minutes, indicating the eye drop formulations 
did not sustain the drug release. Sustained drug 
release from DH formulations was attributed to 
the entrapment of drug molecules in the PEG 
network and the encapsulation by the 
nanodomains inside the dendrimers.  
 
 
A 
B 
Figure 3.4 In vitro release of brimonidine (A) and timolol 
maleate (B) in pH 7.4 PBS at 37C 
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3.4.4 Enhanced drug uptake 
The intracellular uptake of brimonidine and timolol maleate by HCETs was substantially 
increased by the DH formulations. According to the analysis of drug content in the cells treated 
with the DH and eye drop formulations(Figure 3.5), the eye drop brought about an uptake of 
3.81±0.28 % for brimonidine and 49.40±2.60 % for timolol maleate, respectively. With the aid 
of DH formulations, brimonidine uptake was 76.17±19.47 % and timolol uptake was 
69.10±13.70 %. The uptake of hydrophobic brimonidine mediated with the DH formulation was 
19-fold higher than its uptake mediated with the eye drop formulation (P = 0.003). This 
dramatically enhanced cellular uptake of brimonidine was attributed to its increased water 
solubility and its even dispersion in the gel network.  
 
Figure 3.5 Drug uptake in HCET cells treated with DH and eye drop formulations. 
3.4.5 Ex vivo transcorneal transport 
Transcorneal transport of anti-glaucoma drugs was also enhanced by the DH. 
Brimonidine and timolol maleate crossed the cornea at a significantly higher rate with the 
application of the DH formulation. For brimonidine, statistically significant differences (p < 
0.05) were observed in its transcorneal transport starting from 3 hours (Figure 3.6-A). For 
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timolol maleate, statistically significant differences (p < 0.001) were observed in its transcorneal 
transport starting from 2 hours (Figure 3.6-B). At 6 hours, 1.06±0.18 % of brimonidine had 
cumulatively transported across the cornea, while 13.54±1.83 % of timolol maleate had 
cumulatively transported across the cornea. In contrast, the eye drop formulation only resulted in 
cumulative transport of 0.77±0.23 % for brimonidine and 6.03±1.55 % for timolol maleate. The 
cumulative transport of timolol maleate was much higher than that of brimonidine at the end of 6 
hours, regardless of formulation type. This might be attributed to the differences in drug 
physicochemical properties such as LogD, which is the most critical parameter influencing 
transcorneal drug transport.  
 
3.4.6 Ex vivo eye uptake 
This study was conducted to assess the ex vivo uptake of brimonidine and timolol maleate 
in ocular tissues after 1 hour of topical instillation. The levels of brimonidine from the hydrogel 
formulation were similar to those from the eye drop solution formulation in corneal epithelium, 
stroma, and endothelium (Figure 3.7-A). We observed significantly higher levels of timolol 
maleate from the hydrogel formulation as compared to the eye drop solution in corneal 
 
Figure 3.6 Cumulative transport of brimonidine (A) and timolol maleate (B) mediated with DH and eye drop formulations 
across the bovine cornea. 
A B 
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epithelium, stroma, and endothelium (Figure 3.7-B). Particularly, the timolol maleate levels from 
the hydrogel formulation were 4.6-fold higher in epithelium, 2.6-fold higher in stroma, and 0.4-
fold higher in endothelium. However, significant difference in drug level was not observed in the 
aqueous humor between hydrogel formulation and eye drop formulation for both brimonidine 
and timolol maleate (Figure 3.7-A and Figure 3.7-B), which may be due to the short contact time 
of the formulation with the eye surface and the short duration of the study (1 hour).  
 
3.5 Discussion 
Recently, we have synthesized photocurable dendrimer derivatives, which are PAMAM 
dendrimers tethered with multiple polyethylene glycol (PEG) chains and photoreactive acrylate 
groups. Exposing dendrimer-derivatives to UV light triggers crosslinking of the reactive acrylate 
groups, leading to the formation of a DH network. DH integrates the characteristics and 
properties of both a dendrimer and PEG network. The surface charges conferred by terminal 
groups on the dendrimer surface can make the hydrogel polyionic with controllable charge 
density. The interior, hydrophobic core of the dendrimer can encapsulate hydrophobic 
 
Figure 3.7 Uptake of brimonidine (A) and timolol maleate (B) in bovine corneal epithelium, stroma, endothelium, and 
aqueous humor after 1hr topical instillation of DH and eye drop formulations (N=4). 
A B 
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compounds, dramatically increasing their water solubility and loading amounts. Concurrently, 
the crosslinked PEG network can load hydrophilic drugs.  
In our previous approach, PEG chains were conjugated to amine-terminated PAMAM 
dendrimer first and then photoreactive acrylates were introduced to the dendrimer by reacting 
acryloyl chloride ideally with the hydroxyl end groups of PEG chains(15). Acrylate attached to 
PEG would respond to UV light exposure to initiate crosslinking reaction. This approach has 
proven to be valid for gel formation. Due to the possible shielding effect of PEG, acrylate groups 
on the dendrimer surface should be avoided in order to achieve efficient crosslinking. However, 
restricting acrylate groups to the distal end of the conjugated PEG chains was beyond control in 
that approach as acryloyl chloride has reactivity towards free amine group on the dendrimer 
surface. In this work, we modified this approach by reacting acryloyl chloride with PEG diol 
first, to ensure that acrylate was restrictively attached to the end of PEG, and then by coupling 
PEG acrylate to the dendrimer. Photoreactive dendrimer derivatives in aqueous solutions are able 
to become viscous solutions and/or form “no flow” gels in situ upon light exposure by tuning 
their concentration and/or structure parameters including the degree of PEGylation, PEG length, 
and the density of acrylate groups on the dendrimer.  
DH was investigated as a new platform for anti-glaucoma drug delivery. The DH 
formulations displayed good cytocompatibility and could dramatically enhance water solubility 
of hydrophobic anti-glaucoma drugs such as brimonidine. Brimonidine and timolol maleate 
encapsulated into DH were released in a sustained manner. The intracellular uptake of 
brimonidine and timolol maleate by HCETs and their transport across the bovine corneal 
endothelium were substantially increased by DH formulations as opposed to eye drop solution 
formulations. According to ex vivo bovine eye studies, significantly higher levels of timolol 
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maleate in corneal epithelium, stroma and endothelium resulted from the application of the gel 
formulation. PAMAM dendrimer is known to transiently open tight junctions in the intestinal 
epithelium(60). Thus, one possible explanation for the higher uptake in the DH formulations is 
the temporary disruption of the tight junctions in the corneal epithelial cell layer. The in vitro and 
ex vivo studies indicate that dendrimer hydrogel formulations are capable of enhancing delivery 
of anti-glaucoma drugs and represent a novel platform to deliver drugs for the treatment of 
ocular diseases such as glaucoma. As a consequence, reduced dosing frequency and sustained 
efficacy of ocular drugs are expected and will be studied in future work. 
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Chapter 4 Surface Engineering of Macrophages with Nanoparticles to 
Generate a Cell-Nanoparticle Hybrid Vehicle for Drug Delivery  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following chapter is adapted from a manuscript accepted in the International Journal of 
Nanomedicine: Published 22 December 2009, Volume 2010(5), Pages 25-36, DOI: 
https://doi.org/10.2147/IJN.S8339 
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4.1 Abstract 
Tumors frequently contain hypoxic regions that result from a shortage of oxygen due to 
poorly organized tumor vasculature. Cancer cells in these areas are resistant to radiation- and 
chemo-therapy, limiting the treatment efficacy. Macrophages have inherent hypoxia-targeting 
ability and hold great advantages for targeted delivery of anticancer therapeutics to cancer cells in 
hypoxic areas. However, most anticancer drugs cannot be directly loaded into macrophages 
because of their toxicity. In this work, we designed a novel drug delivery vehicle by hybridizing 
macrophages with nanoparticles through cell surface modification. Nanoparticles immobilized on 
the cell surface provide numerous new sites for anticancer drug loading, hence potentially 
minimizing the toxic effect of anticancer drugs on the viability and hypoxia-targeting ability of the 
macrophage vehicles. In particular, quantum dots and 5-(aminoacetamido) fluorescein-labeled 
polyamidoamine dendrimer G4.5, both of which were coated with amine-derivatized polyethylene 
glycol, were immobilized to the sodium periodate-treated surface of RAW264.7 macrophages 
through a transient Schiff base linkage. Further, a reducing agent sodium cyanoborohydride was 
applied to reduce Schiff bases to stable secondary amine linkages. The distribution of nanoparticles 
on the cell surface was confirmed by fluorescence imaging, and it was found to be dependent on 
the stability of the linkages connecting nanoparticles to the cell surface.  
4.2 Introduction 
The cell membrane, a semipermeable lipid bilayer, defines the cell boundary and consists 
of lipids, proteins and carbohydrates that are responsible for selective uptake of molecules, cell-
cell interactions, cell-matrix interactions, and many other vital cell activities. Because of the 
importance of cell surface interactions to cell and tissue function, various cell surface engineering 
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approaches have been explored to modify the cell surface to manipulate cell behavior and 
function(61, 62).  
Considerable progress has been made in introducing non-native chemical species to the 
cell membrane permitting a wide range of applications in biology, medicine, drug delivery, and 
tissue engineering(36). A molecule of interest can be attached to the cell surface through a fatty 
tether including GPI-anchored proteins(63) and cholesterol-tethered compounds(64). A viable 
alternative is to apply enzyme-catalyzed chemical reactions to modify carbohydrates on the cell 
surface. For example, existing surface glycoforms can be utilized as acceptors for reactions with 
an exogenously applied glycosyltransferase and appropriate activated sugar donor(61, 65). Sialic 
acids are the most common terminal sugar residue on the cell surfaces and play an important role 
in cell adhesion and recognition. Unnatural sialic acid precursors can be incorporated into cell 
surface glycoforms by metabolic engineering(66). Direct covalent reactions can also be applied to 
enable chemical modification of cell surfaces(67, 68). One possible approach is to couple 
biomolecules of interest to the cell surface via reactive cell surface groups such as aldehydes and 
ketones(35, 69). The generation of these reactive cell surface groups may be achieved by direct 
chemical or enzymatic treatment, or by the metabolic incorporation of an unnatural molecule that 
contains the chosen chemical species. 
Cell surface engineering has generated tremendous advantages for drug delivery and tissue 
engineering. For example, a synthetic adenovirus receptor inserted to the cell surface via a 
metabolic engineering approach facilitates the entrance of adenovirus into cells that are normally 
resistant to infection by this virus(70). Uptake of exogenous proteins could be enhanced by 
inserting appropriate synthetic receptors(71). Selectively killing tumor cells could be realized by 
controlling the targeting of an antibody through tagging tumor cells with a non-natural sugar into 
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the polysialic acid molecules on the cell surface(72). Cell surface modification approaches have 
also been applied to generate three-dimensional cell aggregates or tissue-engineered constructs 
through cell crosslinking(73). A recent study reported that polyethylene glycol (PEG) can be 
attached to the surface of islets to circumvent immune rejection during transplantation of 
pancreatic islets from donor to a patient(68).  
In this work, we designed a novel hypoxia-targeted drug delivery vehicle by hybridizing 
macrophages with nanoparticles through cell surface modification. Tumors frequently contain 
hypoxic regions that result from a shortage of oxygen due to poorly organized tumor vasculature. 
Cancer cells in these areas are resistant to radiation- and chemo-therapy, limiting the treatment 
efficacy(29). Macrophages and monocytes have inherent hypoxia-targeting ability and hold great 
advantages for selective delivery of anticancer therapeutics to cancer cells in hypoxic areas(27, 29, 
74, 75). However, most anticancer drugs cannot be directly loaded into macrophages or monocytes 
because of their toxicity. Hybridizing a macrophage cellular vehicle with a synthetic carrier, 
particularly nanoparticles, may represent a novel approach for effective delivery of anticancer 
drugs to hypoxic regions in solid tumors. Immobilizing nanoparticles on the cell surface provide 
numerous new sites for anticancer drug loading, hence potentially minimizing the toxic effect of 
anticancer drugs on the viability and hypoxia-targeting ability of the macrophage or monocyte 
vehicles. 
The focus of the current work was to demonstrate the feasibility of immobilizing 
nanoparticles including polyamidoamine (PAMAM) dendrimers and quantum dots (Qdots) to the 
macrophage surface through cell surface chemical modification. Dendrimers are highly branched 
macromolecules with low polydispersity and well-defined surface functionality. Utility of 
dendrimers in this work allowed us to take advantage of their versatility to explore optimal 
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approaches for cell-nanoparticle hybridization and realize a high drug payload and assembly of 
multiple functional entities necessary for hybridization and drug delivery. Commercially 
available quantum dots coated with amine-derivatized PEG was also studied for cell-nanoparticle 
hybridization. Qdots have been explored for fluorescence imaging of living cells(76). Although 
the limited number of surface groups of Qdots is not advantageous for drug loading, hybridizing 
cells with Qdots possessing long-term photostability offers a noninvasive way for cell tracking in 
vivo and would provide further evidence to demonstrate the feasibility of the cell nanoparticle 
hybridization approach explored in this work. 
 
4.3 Experimental 
4.3.1 Materials 
Qdot® 525 ITK™ amino (PEG) quantum dots(QD525) and 5-(aminoacetamido) 
fluorescein (AAF) were purchased from Invitrogen (Carlsbad, CA). PAMAM G4.5 dendrimer was 
purchased from Dendritech (Midland, MI). PEG diamine (MW= ~ 3350 g mol-1), N-
hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC), sodium phosphate buffer (10×), sodium periodate (NaIO4), and sodium cyanoborohydride 
(NaCNBH3) were purchased from Sigma-Aldrich (St. Louis, MO). 4’,6-diamidino-2-phenylindole 
(DAPI), Dulbecco’s modified Eagle medium (DMEM), sodium hydroxide, paraformaldehyde, 
phosphate-buffered saline (PBS), fetal bovine serum (FBS), penicillin, and Trypan blue were 
purchased from Fisher Scientific (Pittsburgh, PA). 
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4.3.2 Preparation of AAF-labeled PEGylated G4.5 dendrimers (AAF-G4.5-PEG) 
Synthesis 
The synthesis of G4.5-PEG followed our previous work[21].19 Upon removal of methanol 
from G4.5 PAMAM stock solution by rotary evaporation, G4.5 PAMAM dendrimer (5 mg) was 
dissolved in 2 mL of sodium PBS (0.1 M, pH=5.5). To this solution were added 5.4 mg of EDC 
and 3.2 mg of NHS. After a 15 minute reaction at room temperature, 68.5 mg of PEG diamine 
(MW= ~ 3350 g mol-1) predissolved in the buffer solution was added to the reaction solution 
dropwise. Then 1.4 mg of AAF predissolved in the buffer was slowly added to the reaction 
solution. The reaction mixture solution was stirred in the dark overnight. The resultant AAF-G4.5-
PEG nanoparticles were purified by dialysis and then freeze dried. 
 
Proton nuclear magnetic resonance (1H NMR) spectroscopy 
The 1H NMR spectra of dendrimer derivatives were recorded on a Varian Mercury-300 
MHz NMR spectrometer (Varian, Palo Alto, CA). The solvent used was deuterium water (D2O), 
which has a chemical shift of 4.8 ppm. 
 
Fluorescence spectroscopy  
Fluorescence emission spectra of AAF and AAF-G4.5-PEG in water were recorded on a 
Varian Cary Eclipse fluorescence spectrophotometer with an excitation wavelength of 488 nm.  
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4.3.3 Preparation of macrophage-nanoparticle hybrid vehicles  
As illustrated in Figure 4.1, nanoparticles (Qdots or AAF-G4.5-PEG) were coupled to the 
surface of macrophages via either a transient Schiff base linkage or a stable secondary amine 
linkage.  
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Figure 4.1 Hybridization of nanoparticles and macrophage through cell surface modification. Sialic acid residues on the cell surface 
are modified with sodium periodate to generate aldehydes. Aldehydes react with amine group of PEG conjugated to the 
nanoparticle surface to form Schiff bases. Schiff bases can be further reduced to stable secondary amine linkages using sodium 
cyanoborhydride. 
Macrophage-nanoparticle hybrids with a transient linkage (macrophage-T-nanoparticle 
hybrids) 
RAW264.7 macrophages were plated on coverslips at a density of 1.2×104 cells/well. At 
70% confluence, the cells were treated with 0.1 mM cold NaIO4 in 100 µL PBS(pH 7.4), incubated 
with shaking for 15 minutes at 4 °C in the dark, and then rinsed with cold PBS three times to 
remove NaIO4.(73). Following the NaIO4 treatment, the cells were incubated with 12 µg of 
nanoparticles dissolved in 100 µL of PBS for 0-24 hours. The resultant macrophage-T-
nanoparticle hybrids were washed with PBS and incubated in PBS. At predetermined time points, 
macrophage-T-nanoparticle hybrids were fixed with 300 µL 4% paraformaldehyde for 
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fluorescence or confocal imaging. Untreated macrophages incubated with nanoparticles were used 
as a control. 
 
Macrophage-nanoparticle hybrids with a stable linkage (macrophage-S-nanoparticle hybrids) 
Macrophage-T-nanoparticle hybrids were further treated with 100 µL 0.1 mM NaCNBH3 
for 1~2 hours to convert the transient Schiff base linkages to stable amide linkages, washed with 
PBS, and incubated in PBS. At predetermined time points, macrophage-T-nanoparticle hybrids 
were fixed with 4% paraformaldehyde for imaging. Untreated macrophages incubated with 
nanoparticles were used as a control.  
 
4.3.4 pH-dependent cell viability assay 
Since RAW264.7 macrophages were subjected to surface modification and the rate of the 
stabilizing amide reaction is pH-depdendent, the effect of pH of modifying solutions on their 
viability was studied. In brief, RAW264.7 macrophages were initially incubated for two hours in 
media of different pH values including DMEM (pH 7.4, control) and PBS (pH 8, pH 9 and pH 10, 
adjusted with sodium hydroxide), washed with PBS (pH 7.4) three times, and grown in DMEM 
supplemented with 10% FBS and 5% penicillin for 48 hours. Viable cells were counted by using 
the Trypan blue assay. In addition, toxicity of 0.1mM NaCNBH3 in DMEM at pH 7.4 was also 
evaluated. Cell viability (%)= total number of viable cells in each group/total number of viable 
cells in the control × 100. 
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4.3.5 Fluorescence image analysis 
True-color fluorescence images of the macrophage-nanoparticle hybrids were taken under 
a Zeiss Axiovert 200 inverted fluorescence microscope (Carl Zeiss AG, Oberkochen, Germany) 
or with a Leica TCS-SP2 AOBS confocal laser scanning microscope(Leica, Solms, Germany). 
DAPI nuclear stain was applied for colocalization of nanoparticles. Images were analyzed with 
ImageJ software (National Institutes of Health, Bethesda, MD).   
 
4.4 Results and Discussion 
4.4.1 Preparation of macrophage-nanoparticle hybrids 
In this study commercial QD525 quantum dots coated with an amine-derivatized PEG layer 
and synthesized PEGylated carboxyl-terminated PAMAM dendrimer G4.5 were employed for 
hybridization with macrophages. PEGylated G4.5 PAMAM dendrimer was labeled with AAF to 
allow confirmation of immobilization of nanoparticles on the cell surface by fluorescence imaging. 
Polyanionic G4.5 PAMAM dendrimer has a relatively high number of surface groups, negligible 
toxicity and immunogenicity, and favorable biodistribution(77). The negatively charged 
dendrimers have demonstrated negligible cellular uptake due to their low non-specific interaction 
with the negatively charged cell surface. Inclusion of PEG provides dendrimers with favorable 
pharmacokinetic and tissue distribution and reduces potential accumulated toxicity and 
immunogenicity of the nanoparticles. Importantly, PEG helps nanoparticles to escape from 
phagocytosis of macrophages. This is a critical step for constructing the proposed hybrid delivery 
system. PEGylated dendrimers of larger molecular weight and with more branches tend to have a 
lower accumulation in cells as demonstrated previously(78).  
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Similarly to the QD525 employed in this study, PEGylated G4.5 was designed to have 
amine-derivatized PEG chains on the surface, based on which cell surface modification chemistry 
was explored. PEGylated dendrimers have been well characterized previously(38, 39, 56, 79, 80). 
According to the 1H-NMR measurement, an average of eight PEG chains were coupled to G4.5. 
PEGylated G4.5 was labeled with a moderately water-soluble fluorescence probe, AAF. As shown 
in Figure 4.2, AAF coupled to the dendrimer has an emission wavelength of 515 nm, which is 
identical to the emission wavelength of AAF. The unaltered emission wavelength of AAF 
following this coupling strategy was also found in a previous report(81). Furthermore, the 
fluorescence emission intensity of AAF coupled to PEGylated G4.5 is significantly higher than 
that of AAF prepared in water at saturation, suggesting that AAF coupled to PEGylated G4.5 has 
higher water solubility than its unmodified form. The increase in the water solubility of AAF was 
attributed to the successful conjugation of AAF to the PEGylated dendrimer.  
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Figure 4.2 Fluorescence emission spectra of AAF and AAF-G4.5-PEG. 
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A number of methods have been developed to enable the chemical modification of cell 
surfaces. In this project, we employed a simple and well-documented methodology to immobilize 
nanoparticles to the macrophage cell surface. In particular, sialic acid residues embedded on the 
cell surface were converted to aldehydes with sodium periodate. Our results showed that the 
toxicity of NaIO4 was negligible at the concentration of 0.1 mM. This was supported by the work 
of Ong and coworkers(73). Aldehydes reacted with primary amine end groups of PEG on the 
nanoparticle surface to form Schiff bases. Schiff base linkage is labile and can be cleaved in 
aqueous solution by hydrolysis. Accordingly, the macrophage-T-nanoparticle hybrids constructed 
are expected to readily release nanoparticles through the cleavage of the transient Schiff base 
linkages. We also applied a reducing agent, sodium cyanoborohydride, to reduce Schiff bases to 
stable secondary amine linkages(37). It has been reported that sodium cyanoborohydride has high 
specificity toward the Schiff base. According to our cell viability studies (Figure 4.3), sodium 
cyanoborohydride at 0.1 mM was nontoxic to RAW264.7 macrophages. As the reaction proceeds 
more efficiently at basic pH(82). the viability of RAW264.7 macrophages at high pH (8-10) was 
evaluated to determine whether the immobilization chemistry can be performed at high pH. As 
shown in Figure 4.3, pH affects the cell viability. The viability of RAW264.7 macrophages 
remains intact at pH 8 or pH 7.4 with sodium cyanoborohydride. The cell viability dropped slightly 
to 88% at pH 9. By contrast, the viability was reduced drastically to 52% at pH 10. The results 
suggest that mild basic pH has a minimal impact on the viability of RAW264.7 macrophages and 
the optimum pH within that range can be explored for increasing the immobilization efficiency.  
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Figure 4.3 pH-dependent viability of RAW264.7 macrophages. Cells were incubated for two hours at the indicated pH and then 
assessed by the Trypan blue assay 48 hours later. Nontoxicity of 0.1mM sodium cyanoborohydride in DMEM at pH 7.4 was 
confirmed. Note: Bar = SD. Abbreviations: DMEM, Dulbecco’s modified Eagle’s medium. 
4.4.2 Fluorescence image analysis of macrophage-Qdot hybrids 
Fluorescence microcopy and confocal microscopy were applied to confirm the 
hybridization of nanoparticles with macrophages. As shown in Figure 4.4, both macrophage-T-
nanoparticle hybrids and macrophage-S-nanoparticle hybrids prepared with QD525 exhibit strong 
fluorescence intensity at the edge of the cells, clearly outlining the cell surface. Qualitatively, more 
QD525 were taken up in macrophage-T-nanoparticle hybrids as opposed to macrophage-S-
nanoparticle hybrids, reflecting the stability of the linkage between the nanoparticles and the cell. 
Confocal microscopy images in z-sections were taken to further examine the distribution of QD525 
over the course of time. Without cell surface modification, QD525 were phagocytosed quickly and 
evenly distributed in the cytoplasm (Figure 4.5-A 4h and 14h). Although QD525 were still 
internalized, a significant amount of QD525 accumulated at the edge of the cells treated with 
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sodium periodate (Figure 4.5-B) or a 
combination of sodium periodate and 
sodium cyanoborohydride (Figure 
4.5-C). QD525 immobilized on the 
cell surface through a stable 
secondary amine bond displayed 
good stability overnight (Figure 4.5-
C-14h). In contrast, QD525 linked to 
the cell surface via Schiff base 
linkages were found to be re-
distributed in the cell overnight 
(Figure 4.5-B-14h).  
 
A 
B 
Figure 4.4 Fluorescence microscopy images of macrophage-Qdot hybrids. A) 
Macrophage-T-Qdot. B) Macrophage-S-Qdot. Original magnification 400x, 
scale bar 10 µm. 
10 µm 
10 µm 
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Figure 4.5 Confocal microscopy images (630×) of macrophage-Qdot hybrids at 4 hours (left panel) or 14 hours (right panel) post 
treatment. A) Qdots incubated with untreated macrophages (control); B) Macrophage-T-Qdot hybrids;(C) Macrophage-S-Qdot 
hybrids. 
4h 
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A 
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4.4.3 Fluorescence image analysis of macrophage-dendrimer hybrids 
Macrophages hybridized with AAF-labeled PEGylated PAMAM dendrimer G4.5 were 
also studied. As shown in Figure 4.6-A, the level of the internalization of AAF-G4.5-PEG by 
untreated macrophages is low. This confirmed that cationic surface charges and PEGylation indeed 
helped to reduce nonspecific internalization by macrophages. Further, an apparently biased 
distribution of AAF-G4.5-PEG nanoparticles was observed on the cell surface of macrophages 
that were treated with sodium periodate (Figure 4.6-B) or the combination of sodium periodate 
and sodium cyanoborohydride (Figure 4.6-C). A significant increase in fluorescence intensity of 
macrophage-T-dendrimer hybrids and macrophage-S-dendrimer hybrids as compared to the 
control suggests that more dendrimer nanoparticles have been immobilized to the cell surface 
and/or internalized by the cells. The amine linkages connecting dendrimers to the cell enabled 
macrophage-S-dendrimer hybrids to carry dendrimers stably on the surface for an extended period 
of time. We also observed that when the surface-treated RAW264.7 macrophages were incubated 
with the same amount of AAF-G4.5-PEG (12 µg), a condition of a high concentration (12 µg/100 
µL) and a short incubation (1 minute) and that of a low concentration (12 µg /1.5 mL) and a long 
incubation (10 minutes) resulted in a similar hybridization efficiency as determined by confocal 
microscopy measurements. Cell viability remained good during the surface treatment. 
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To further evaluate the intracellular localization of nanoparticles, we performed a 
colocalization assay on AAF-G4.5-PEG with nuclear DAPI staining. Clearly shown in Figure 4.7-
A, a significant amount of AAF-G4.5-PEG nanoparticles were internalized within one-minute 
incubation and accumulated evenly in the cytoplasma with no selectivity towards the cell surface 
after overnight culture. Entry of the nanoparticles into nuclei was also observed in the 
macrophages. This became more evident when the cells were incubated with AAF-G4.5-PEG for 
Figure 4.6 Confocal microscopy images (630×) of macrophage-dendrimer hybrids. (A) Untreated macrophages 
incubated with AAF-G4.5-PEG for 10 minutes and fixed immediately(control); (B) Macrophage-T-dendrimer 
hybrids fixed immediately following 10 minute incubation with AAF-G4.5-PEG; (C) Macrophage-S-dendrimer 
hybrids fixed at 14 hours following treatment of sodium cyanoborohydride. 
A B 
C 
20 µm 20 µm 
20 µm 
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an extended period of time (overnight incubation, Figure 4.7-B). In addition, more nanoparticles 
were internalized by the cells following the overnight incubation as indicated by the increase in 
the fluorescence intensity. Macrophage-S-dendrimer hybrids (Figure 4.7-D) show a stronger 
fluorescence intensity at the cell surface and less in nuclei as compared to macrophage-T-
dendrimer hybrids (Figure 4.7-C), confirming that the stability of immobilized dendrimers in 
macrophage-S-dendrimer hybrids was higher than macrophage-T-dendrimer hybrids.  
 
Figure 4.7 Colocalization assay of AAF-G4.5-PEG (green) with nuclei (blue) by confocal microscopy (630×). (A) Control 1: 
untreated macrophages incubated with AAF-G4.5-PEG for 1 minute, cultured overnight (24 hours), then fixed and 
counterstained with DAPI; (B) Control 2: untreated macrophages incubated with AAF-G4.5-PEG overnight (24 hours), then fixed 
and counterstained with DAPI; (C) Macrophage-T-dendrimer hybrids: sodium periodate-treated macrophages incubated with 
AAF-G4.5-PEG for 1 minute, cultured overnight (24 hours), then fixed and counterstained with DAPI; (D) Macrophage-S-
dendrimer hybrids: sodium periodate-treated macrophages incubated with AAF-G4.5-PEG for 1 minute, treated with sodium 
cyanoborohydride, cultured overnight (24 hours), then fixed and counterstained with DAPI.  
It is apparent that fluorescently labeled nanoparticles were taken into the macrophages 
after each treatment. Qualitatively, there is a uniform distribution of fluorescence throughout the 
DAPI 
5’ AAF 
Merge 
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untreated control groups, suggesting cellular uptake pathways are responsible for this 
occurrence. Following surface modification, a pronounced ring of fluorescence is observed 
towards the cell surface. Quantitative analysis of the distribution of nanoparticle fluorescence 
was attempted with the intensity profiled generated by ImageJ software (Figure 4.8). Since all 
confocal images were taken under identical image acquisition settings, the fluorescence intensity 
profiles-generated allowed us to quantitatively analyze fluorescence distribution in individual 
cells based on their relative fluorescence intensity. For each group, three representative cells 
were chosen and analyzed. Individual cells were measured three times from different orientations 
with each orientation approximately bisecting midlines. From each profile, intensity values were 
recorded from fluorescence peaks at the two cell boundaries and from a fluorescence peak near 
the midline of each trace. The results are summarized in Table 4.1. The results from the intensity 
traces show that for a nanoparticle incubation of 1 minute there is a 20.8% more fluorescence at 
the cell boundaries versus the cell center.  For an overnight nanoparticle incubation, there was an 
even distribution of fluorescent intensity where the cell walls exhibited a fluorescence value that 
was 99.8% of the fluorescence of the midpoint of the slice.  Surface modification drastically 
increased the ratio of fluorescence between the cell walls versus the cell interior.  The 
macrophage-T-nanoparticle hybrids showed an 85.2% increase in fluorescence near the cell 
exterior, whereas the macrophage-S-nanoparticle hybrids showed a 94.4% increase in cell wall 
fluorescence. Based on these measurements we show that there is markedly more fluorescence 
near the cell surface for surface-treated groups, whereas there is an even distribution of 
nanoparticles in the control groups. 
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Figure 4.8 Quantitative analysis of the distribution of fluorescence intensity in representative cells. (A) Control 1; (B) Control 2; 
(C) Macrophage-T-dendrimer hybrid; (D) Macrophage-S-dendrimer hybrid. The treatment conditions are detailed in Figure 4.7 
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Table 4.1 Summary of the distribution of AAF fluorescence intensity in macrophages subjected to various treatments as 
indicated below. 
Group [L] [I] [R] ([L]+[R])/[I] (%) 
A 70.3±12.5 55.0±3.7 62.6±7.3 120.8 
B 58.4±10.6 57.8±13.5 57.0±6.4 99.8 
C 64.3±10.2 33.4±8.7 59.3±12.5 185.2 
D 67.5±8.1 33.6±5.2 63.2±6.1 194.4 
 
(A) Control 1; (B) Control 2; (C) Macrophage-T-dendrimer hybrid; (D) Macrophage-S-dendrimer hybrid 
(The treatment conditions are detailed in Figure 4.7). [L], average fluorescence intensity at the 
left cell wall; [I] average fluorescence intensity at the interior of the cell; [R], average 
fluorescence intensity at the right cell wall. The original images (n=3) were analyzed with 
ImageJ.  
 
4.5 Future work 
From a chemistry perspective, this work demonstrated the proof-of-principle of chemically 
hybridizing nanoparticles with macrophages through cell surface modification. The reaction 
conditions explored in this study were mild to the cells. It should be noted that internalization of 
nanoparticles by macrophages seems to be an inevitable process because of their innate phagocytic 
capability. Nonetheless, our studies disclosed that cell surface modification provides a means to 
retard the internalization progress and alter the intracellular distribution of nanoparticles. A 
comprehensive understanding of the trafficking and dynamic distribution of nanoparticles is 
needed in order for us to optimize the hybridization process. Reducing nonspecific phagocytic 
internalization of nanoparticles will be pursued in our laboratory. The sizes of the QD525 and 
PAMAM dendrimers as an important factor affecting nanoparticle internalization by cells will be 
studies. PAMAM dendrimers have a versatile structure ideal for construction of drug delivery 
systems and have been extensively studied by many groups, including us(17, 18, 83, 84). Future 
work will include hybridization of drug-carrying dendrimers and/or QD525 with macrophages and 
studying the delivery efficiency of such a new drug vehicle in terms of drug distribution in hypoxic 
areas using in vitro spheroid models and animal models. 
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4.6 Conclusions 
QD525 and dendrimers were immobilized to the macrophage cell surface either through a 
transient Schiff base linkage or a stable amine linkage. The distribution of nanoparticles on the 
cell surface was confirmed by fluorescence imaging and was found to be dependent on the stability 
of the linkages connecting nanoparticles to the cell surface. Achieving homogeneous distribution 
of anticancer drugs within tumors remains one of the major challenges in cancer chemotherapy 
and is critical for treatment effectiveness. The current study has explored an innovative way of 
utilizing nanoparticles and cellular vehicles for anticancer drug delivery. Development of a cell-
nanoparticle hybrid vehicle through cell surface modification would utilize the best aspects of both 
cellular carriers and nanoparticles and may help to improve anticancer drug distribution and 
penetration in tumors. 
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Chapter 5 Summary and Continuing Work 
 
This work explored the use of PAMAM dendrimers in two drug-delivery systems. These 
preliminary studies have provided promising results for continuing the work on dendrimers in 
hydrogels and in cell-surface engineering.  
5.1 DH formulations 
DH formulations were shown to increase the loading of drug molecules, increase 
transcorneal drug delivery, and exhibit sustained-delivery of drug molecules. These DHs show 
potential to reduce dosing frequency through sustained-delivery and increase drug bioavailability 
through increased precorneal residence and transcorneal transport. The in vitro and ex vivo 
studies explored in this work set the stage for continued experiments in vivo.  
Based on the work in this thesis, IOP-lowering ability and sustained-delivery of 
concomitant DH was studied in rabbits. Continued work combined poly(lactic-co-glycolic acid) 
(PLGA) nanoparticles in DH  formulations; this work found sustained drug levels of brimonidine 
and timolol maleate for one week following a single dose in rabbit ocular tissues. This PLGA-
DH system also led to a sustained IOP reduction of 18% or higher for 4 days. This platform 
shows continuing promise for treating chronic eye diseases, including glaucoma(85). 
 This project has evolved from the use of a photoinitiator and UV-curing system based on 
concerns of potential hazards and stability issues of the DH formulations. The Eosin-Y 
photoinitiator and UV system works on the mechanism of creating free radicals for crosslinking 
 
 
57 
 
within the PEG network and free radicals can be harmful to tissues, so a newer system has been 
devised and tested to avert these issues. New work focuses on the creation of electrospun 
dendrimer-PEG nanofiber mats (DNF) with the incorporation of poly(ethylene oxide) in a single 
drug formulation of brimonidine tartrate. Compatibility and efficacy of the DNFs were studied in 
rats over a three week period. It was found that DNFs and eye drop formulations had similar 
responses after single doses; however, DNF formulations showed increased efficacy attributed to 
accumulation of dendrimers in the anterior chamber of the eye over the three week trial(86, 87). 
 In related work on dendrimer hydrogels in our lab, a new approach to hydrogel synthesis 
utilizes biorthogonal chemistry. This work uses copper-free click chemistry for the crosslinking 
of DH as an alternative approach to potentially disruptive photoinitiators. Click chemistry uses 
the high reactivity of alkynes towards azides for efficient coupling of synthetic molecules. Using 
this click chemistry approach, dendrimers were loosely entangled in a physical network for the 
sustained delivery of drug molecules. This approach offers catalyst-free chemistry and is highly 
customizable for use in a variety of applications(87). 
5.2 Cell-surface modified macrophages 
In this work, distribution of nanoparticles on RAW264.6 cell surfaces was observed by 
fluorescence microscopy and was found to be dependent on the stability of the linkages tethering 
nanoparticles to the cell surface. The current work explored the proof-of-concept for a novel 
approach to loading anti-cancer drugs onto immune cells via PAMAM dendrimers. Future work 
includes optimization of the hybridization conditions, synthesis of anti-cancer drug-loaded 
dendrimers, quantification of macrophage-dendrimer drug-loading capacity, and studying the 
infiltration of hybridized-macrophages into tumor models. The results from this study, indicate 
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that a hybridized cellular delivery system is feasible and could potentially improve drug-
targeting in a range of applications. 
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